Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mereo Biopharma Group Plc ADR (MREO)

Mereo Biopharma Group Plc ADR (MREO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 530,172
  • Shares Outstanding, K 140,257
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -29,470 K
  • 60-Month Beta 0.88
  • Price/Sales 53.44
  • Price/Cash Flow N/A
  • Price/Book 12.47
Trade MREO with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.01
  • Most Recent Earnings $-0.01 on 05/15/24
  • Next Earnings Date 08/21/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 104.84% ( +7.81%)
  • Historical Volatility N/A
  • IV Percentile 40%
  • IV Rank 20.57%
  • IV High 489.29% on 09/21/23
  • IV Low 5.30% on 05/15/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 578
  • Volume Avg (30-Day) 406
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 26,295
  • Open Int (30-Day) 24,609

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.88 +9.54%
on 09/17/24
5.02 -15.34%
on 08/23/24
-0.19 (-4.28%)
since 08/20/24

Most Recent Stories

More News
Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo”...

MREO : 4.25 (-0.70%)
Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five

Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo”...

MREO : 4.25 (-0.70%)
Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders

Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo”...

MREO : 4.25 (-0.70%)
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

LONDON and MOUNTAIN VIEW, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a...

MREO : 4.25 (-0.70%)
Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE) 1 Complete Response (CR), 2...

MREO : 4.25 (-0.70%)
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

LONDON and REDWOOD CITY, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage...

MREO : 4.25 (-0.70%)
Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET...

MREO : 4.25 (-0.70%)
Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET...

MREO : 4.25 (-0.70%)
Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

LONDON and REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage...

MREO : 4.25 (-0.70%)
Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights

LONDON and REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage...

MREO : 4.25 (-0.70%)
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar